Evaxion A/S (EVAX) Form 6-K — Oct 19, 2026
Evaxion reported that all patients at three-year follow-up in the phase 2 trial of personalized cancer vaccine EVX-01 in advanced melanoma maintained their clinical responses, with no tumor progression observed. In year three, patients received EVX-01 as stand-alone therapy, demonstrating durability beyond the initial KEYTRUDA combination period. The new data supplement previously reported two-year results showing a 75% objective response rate, 25% complete response rate, and tumor reduction in 15 of 16 enrolled patients. Vaccine-induced immune responses were seen in all patients, with 86% of neoantigens generating potent T-cell responses.
Key figures
- Presentation
- ESMO 2026 poster 2006P, October 24, 2026; webinar October 29, 2026
- Extension responders
- 6 of 12 responders
- Complete response rate
- 25%
- Objective response rate
- 75%
- Patients with tumor reduction
- 15 of 16
- Patients with deepened response
- 54%
- Patients responding at two years
- 92%
- Neoantigens generating tcell responses
- 86%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.